Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects

Journal of Immunology

Volumn 174, Issue 7, 2005, Pages 3925-3931

  Burdelya, Lyudmila ^a,d   Kujawski, Maciej ^a   Niu, Guilian ^a   Zhong, Bin ^a   Wang, Tianhong ^b   Zhang, Shumin ^a   Kortylewski, Marcin ^a   Shain, Kenneth ^a   Kay, Heidi ^c   Djeu, Julie ^a   Dalton, William ^a   Pardoll, Drew ^b   Wei, Sheng ^a   Yu, Hua ^a,e  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CHEMOATTRACTANT; NITRIC OXIDE; NITRITE; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL INFILTRATION; CYTOSTASIS; EFFECTOR CELL; GEL MOBILITY SHIFT ASSAY; GENETIC TRANSFECTION; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; LYMPHOCYTE MIGRATION; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MELANOMA CELL; MOUSE; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; SECRETION; TUMOR GROWTH;

EID: 20144376844     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.174.7.3925     Document Type: Article

References (40)

1. Blattman, J. N., and P. D. Greenberg. 2004. Cancer immunotherapy: a treatment for the masses. Science 305:200.
2. Bowman, T., R. Garcia, J. Turkson, and R. Jove. 2000. STATs in oncogenesis. Oncogene 19:2474.
3. Buettner, R., L. B. Mora, and R. Jove. 2002. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin. Cancer Res. 8:945.
4. Yu, H., and R. Jove. 2004. The STATs of cancer - new molecular targets come of age. Nat. Rev. Cancer 4:97.
5. Catlett-Falcone, R., T. H. Landowski, M. M. Oshiro, J. Turkson, A. Levitzki, R. Savino, G. Ciliberto, L. Moscinski, J. L. Fernandez-Luna, G. Nunez, et al. 1999. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10:105.
6. Epling-Burnette, P. K., J. H. Liu, R. Catlett-Falcone, J. Turkson, M. Oshiro, R. Kothapalli, Y. Li, J. M. Wang, H. F. Yang-Yen, J. Karras, et al. 2001. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J. Clin. Invest. 107:351.
7. WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling. Oncogene 19:5419.
8. Bowman, T., M. A. Broome, D. Sinibaldi, W. Wharton, W. J. Pledger, J. M. Sedivy, R. Irby, T. Yeatman, S. A. Courtneidge, and R. Jove. 2001. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc. Natl. Acad. Sci. USA 98:7319.
9. Niu, G., R. Heller, R. Catlett-Falcone, D. Coppola, M. Jaroszeski, W. Dalton, R. Jove, and H. Yu. 1999. Gene therapy with dominant-negative STAT3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res. 59:5059.
10. Wang, T., G. Niu, M. Kortylewski, L. Burdelya, K. Shain, S. Zhang, R. Bhattacharya, D. Gabrilovich, R. Heller, D. Coppola, W. Dalton, R. Jove, D. M. Pardoll, and H. Yu. 2004. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med. 10:48.
11. Di Carlo, E., G. Forni, L. PierLuigi, M. P. Colombo, A. Modesti, and M. Piero. 2001. The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood 97:339.
12. Takiguchi, K., H. Inagawa, T. Nishizawa, C. Kohchi, and G. Soma. 2002. Perspectives for antitumor therapy based on the recognition mechanism by which macrophages identify undesirable foreign and native cells and molecules. Anticancer Res. 22:4277.
13. Sica, A., A. Saccani, and A. Mantovani. 2002. Tumor-associated macrophages: a molecular perspective. Int. Immunopharmacol. 2:1045.
14. Klimp, A., E. de Vries, G. Scherphof, and T. Daemen. 2002. A potential role of macrophage activation in the treatment of cancer. Crit. Rev. Oncol. Hematol. 44:143.
15. Umansky, V., and V. Schirrmacher. 2001. Nitric oxide-induced apoptosis in tumor cells. Adv. Cancer Res. 82:107.
16. Xie, K., and S. Huang. 2003. Contribution of Nitric oxide-mediated apoptosis to cancer metastasis inefficiency. Free Radical Biol. Med. 34:969.
17. Juang, S., K. Xie, L. Xu, Q. Shi, Y. Wang, J. Yoneda, and I. Fidler. 1998. Suppression of tumorigenicity and metastasis of human renal carcinoma cells by infection with retroviral vectors harboring the murine inducible nitric oxide synthase gene. Hum. Gene Ther. 9:845.
18. Xie, K., Z. Dong, and I. J. Fidler. 1996. Activation of nitric oxide synthase gene for inhibition of cancer metastasis. J. Leukocyte Biol. 59:797.
19. Xie, K., and I. J. Fidler. 1998. Therapy of cancer metastasis by activation of the inducible nitric oxide synthase. Cancer Metastasis Rev. 17:55.
20. Niu, G., T. Bowman, M. Huang, S. Shivers, D. Reintgen, A. Daud, A. Chang, A. Kraker, R. Jove, and H. Yu. 2002. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 21:7001.
21. Turkson, J., S. Zhang, J. Palmer, H. Kay, L. Mora, J. Stanko, S. Sebti, H. Yu, and R. Jove. 2004. Inhibition of constitutive Stat3 activation by novel platinum complexes with potent antitumor activity. Mol. Can Ther. 3:1533.
22. Turner, J. G., A. L. Rakhmilevich, L. Burdelya, Z. Neal, M. Imboden, P. M. Sondel, and H. Yu. 2001. Anti-CD40 antibody induces antitumor and anti-metastatic effects: the role of natural killer cells. J. Immunol. 166:89.
23. + T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 58:3491.
24. Dong, Z., A. H. Staroselsky, X. Qi, K. Xie, and I. J. Fidler. 1994. Inverse correlation between expression of inducible nitric oxide synthase activity and production of metastasis in K-1735 murine melanoma cells. Cancer Res. 54:789.
25. Rot, A., and U. H. von Andrian. 2004. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu. Rev. Immunol. 22:891.
26. Campbell, D. J., C. H. Kim, and E. C. Butcher. 2003. Chemokines in the systemic organization of immunity. Immunol. Rev. 195:58.
27. Schaider, H., M. Oka, T. Bogenrieder, M. Nesbit, K. Satyamoorthy, C. Berking, K. Matsushima, and M. Herlyn. 2003. Differential response of primary and metastatic melanomas to neutrophils attracted by IL-8. Int. J. Cancer 103:335.
28. Hibbs, J. B. J., R. R. Taintor, and Z. Vavrin. 1987. Macrophage cytotoxicity: role for L-arginine deaminase activity and amino nitrogen to nitrate. Science 235:473.
29. Wang, H. H., A. R. McIntosh, B. B. Hasinoff, E. S. Rector, N. Ahmed, D. M. Nance, and F. W. Orr. 2000. B16 melanoma cell arrest in the mouse liver induces nitric oxide release and sinusoidal cytotoxicity: a natural hepatic defense against metastasis. Cancer Res. 60:5862.
30. Dong, Z., X. Qi, K. Xie, and I. J. Fidler. 1993. Protein tyrosine kinase inhibitors decrease induction of nitric oxide synthase activity in lipopolysaccharide-responsive and lipopolysaccharide-nonresponsive murine macrophages. J. Immunol. 151:2717.
31. Bouvet, M., L. M. Ellis, M. Nishizaki, T. Fujiwara, W. Liu, C. D. Bucana, B. Fang, J. J. Lee, and J. A. Roth. 1998. Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res. 58:2288.
32. Nishizaki, M., T. Fujiwara, T. Tanida, A. Hizuta, H. Nishimori, T. Tokino, Y. Nakamura, M. Bouvet, J. A. Roth, and N. Tanaka. 1999. Recombinant adenovirus expressing wild-type p53 is antiangiogenic: a proposed mechanism for bystander effect. Clin. Cancer Res. 5:1015.
33. Vile, R., S. Castleden, J. Marshall, R. Camplejohn, C. Upton, and H. Chong. 1997. Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th-1 like profile of intratumoural cytokine expression. Int. J. Cancer 71:267.
34. Lavnikova, N., L. Burdelya, A. Lakhotia, N. Patel, S. Prokhorova, and D. Laskin. 1997. Macrophage and interleukin-1 induced nitric oxide production and cytostasis in hamster tumor cells varying in malignant potential. J. Leukocyte Biol. 61:452.
35. Turkson, J., D. Ryan, J. S. Kim, Y. Zhang, Z. Chen, E. Haura, A. Laudano, S. Sebti, A. D. Hamilton, and R. Jove. 2001. Phosphotyrosyl peptides block Stat3-mediated DNA-binding activity, gene regulation and cell transformation. J. Biol. Chem. 276:45443.
36. Takeda, K., B. E. Clausen, T. Kaisho, T. Tsujimura, N. Terada, I. Forster, and S. Akira. 1999. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10:39.
37. Lee, C. K., R. Raz, R. Gimeno, R. Gertner, B. Wistinghausen, K. Takeshita, R. DePinho, and D. E. Levy. 2002. Stat3 is a negative regulator of granulopoiesis but is not required for G-CSF-dependent differentiation. Immunity 17:63.
38. Costa-Pereira, A. P., S. Tininini, B. Strobl, T. Alonzi, J. Schlaak, H. Is'harc, I. Gesualdo, S. Newman, I. Kerr, and V. Poli. 2002. Mutational switch of an IL-6 response to an interferon-γ-like response. Proc. Natl. Acad. Sci. USA 99:8043.
39. Darnell, J. E., Jr. 2002. Transcription factors as targets for cancer therapy. Nat. Rev. Cancer 2:740.
40. Cheng, F., H. W. Wang, A. Cuenca, M. Huang, T. Ghansah, J. Brayer, W. G. Kerr, K. Takeda, S. Akira, S. P. Schoenberger, et al. 2003. A critical role for Stat3 signaling in immune tolerance. Immunity 19:425.